Contact Us
Drug Search Results
More Filters [+]

Talmapimod

Alternative Names: talmapimod, scio-469
Latest Update: 2023-12-02
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: MAPK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Talmapimod

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Multiple Myeloma|Preleukemia|Myelodysplastic Syndrome|Bone Marrow Diseases|Arthritis, Rheumatoid

Phase 1: Arthritis, Rheumatoid

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SCIO-469

P2

Completed

Preleukemia|Bone Marrow Diseases|Myelodysplastic Syndrome

2007-12-01

CR005182

P2

Completed

Multiple Myeloma

None

CR005152

P2

Completed

Multiple Myeloma

None

CR005155

P1

Completed

Arthritis, Rheumatoid

None

Recent News Events

Date

Type

Title

12/02/2023

PubMed

 CNS-Active p38α MAPK Inhibitors for the Management of Neuroinflammatory Diseases: Medicinal Chemical Properties and Therapeutic Capabilities.

10/29/2023

PubMed

 Network-Based In Silico Analysis of New Combinations of Modern Drug Targets with Methotrexate for Response-Based Treatment of Rheumatoid Arthritis.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions